ScreenerHero

COGT Cogent Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · cogentbio.com
30.14USD-0.79%Mkt Cap: 5.23B $P/E: —

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyros…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.23B USD
Enterprise Value4.79B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-328.94M USD
Revenue/Share—
Last Price30.14 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees258
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-27.32
PEG—
EV/EBITDA-12.39
EV/Revenue—
P/S—
P/B11.15
EPS (TTM)-2.16
EPS (Forward)-1.11
52W Range
12.9756% of range43.73
52W High43.73 USD
52W Low12.97 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-51.69%
ROA-35.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-264.44M USD
CapEx (TTM)1.55M USD
FCF Margin—
FCF Yield-3.56%
Net Debt-548.04M USD
Net Debt/EBITDA1.42
Balance Sheet
Debt/Equity0.38
Current Ratio13.57
Quick Ratio13.36
Book Value/Sh2.72 USD
Cash/Share4.57 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateNov 9, 2020
Splits
Last Split1:4
Split DateNov 9, 2020
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)55.82 USD
Upside (mean)+85.2%
Target Range45.00 USD – 62.00 USD
45.00+85.2% to mean62.00
# Analysts11
Ownership
Shares Out.173.52M
Float172.56M
Insiders0.42%
Institutions115.22%
Short Interest
Short Ratio11.5d
Short % Float10.50%
Short % Out.10.45%
Shares Short18.13M
Short (prev mo.)18.41M
Technical
SMA 5035.85 (-15.9%)
SMA 20036.33 (-17.0%)
Beta0.31
S&P 52W Chg16.45%
Avg Vol (30d)1.90M
Avg Vol (10d)2.05M
Technical Indicators
RSI (14)29.6
MACD-1.4625
MACD Signal-1.4679
MACD Hist.+0.0054
BB Upper34.86 USD
BB Middle32.20 USD
BB Lower29.54 USD
BB Width16.53%
ATR (14)1.341 USD
Vol Ratio (20d)0.59x